We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it a Good Idea to Invest in Immunocore Stock Right Now?
Read MoreHide Full Article
Immunocore (IMCR - Free Report) is witnessing a strong sales uptake for its sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM).
Kimmtrak is approved in 39 countries, including the United States, the European Union, Canada, and others. The product has been launched in 26 countries worldwide and continues to be the standard of care for mUM in most markets where it has been launched.
Kimmtrak generated sales worth $310 million in 2024, up almost 30% year over year. Kimmtrak sales were driven by increased volume in the United States and expansion into other countries worldwide. In the first quarter of 2025, sales of the drug rose 33.6% on a year-over-year basis to $93.9 million.
IMCR Stock Performance
Year to date, shares of Immunocore have risen 5.8% against the industry’s decline of 5.5%.
Image Source: Zacks Investment Research
IMCR's Label Expansion Studies on Kimmtrak & Other Activities
Several label expansion studies evaluating Kimmtrak both as monotherapy and in combination with other therapies are currently ongoing, targeting an earlier-line setting for melanoma indications.
The company aims to reach more mUM patients with Kimmtrak worldwide in 2025 through additional launches and increased community penetration.
Immunocore is developing its pipeline candidate, brenetafusp, in combination with Bristol Myers’ (BMY - Free Report) blockbuster cancer drug, Opdivo (nivolumab), in a phase III study for treating first-line advanced cutaneous melanoma.
The candidate is also being investigated in early-to-mid-stage studies both as monotherapy and as combination therapy across multiple tumor types, including ovarian cancer and non-small cell lung cancer (NSCLC).
Opdivo, a key growth driver for BMY, is already approved for various oncology indications. BMY recorded $2.26 billion in Opdivo sales in the first quarter of 2025.
With a strong cash position and some clinical milestones expected later this year, investor focus remains on IMCR stock.
IMCR’s Strong Rank & Rising Estimates
Immunocore has a Zacks Rank #1 (Strong Buy). In the past 30 days, estimates for IMCR’s 2025 loss per share have narrowed from $1.50 to 86 cents. During the same time, loss per share estimates for 2026 have narrowed from $1.68 to $1.34.
Immunocore Holdings PLC Sponsored ADR Price and Consensus
In the past 30 days, 2025 earnings estimates for CorMedix have improved from 72 cents per share to 93 cents per share. CRMD shares have surged 51.3% year to date.
CRMD’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 25.82%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is it a Good Idea to Invest in Immunocore Stock Right Now?
Immunocore (IMCR - Free Report) is witnessing a strong sales uptake for its sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM).
Kimmtrak is approved in 39 countries, including the United States, the European Union, Canada, and others. The product has been launched in 26 countries worldwide and continues to be the standard of care for mUM in most markets where it has been launched.
Kimmtrak generated sales worth $310 million in 2024, up almost 30% year over year. Kimmtrak sales were driven by increased volume in the United States and expansion into other countries worldwide. In the first quarter of 2025, sales of the drug rose 33.6% on a year-over-year basis to $93.9 million.
IMCR Stock Performance
Year to date, shares of Immunocore have risen 5.8% against the industry’s decline of 5.5%.
Image Source: Zacks Investment Research
IMCR's Label Expansion Studies on Kimmtrak & Other Activities
Several label expansion studies evaluating Kimmtrak both as monotherapy and in combination with other therapies are currently ongoing, targeting an earlier-line setting for melanoma indications.
The company aims to reach more mUM patients with Kimmtrak worldwide in 2025 through additional launches and increased community penetration.
Immunocore is developing its pipeline candidate, brenetafusp, in combination with Bristol Myers’ (BMY - Free Report) blockbuster cancer drug, Opdivo (nivolumab), in a phase III study for treating first-line advanced cutaneous melanoma.
The candidate is also being investigated in early-to-mid-stage studies both as monotherapy and as combination therapy across multiple tumor types, including ovarian cancer and non-small cell lung cancer (NSCLC).
Opdivo, a key growth driver for BMY, is already approved for various oncology indications. BMY recorded $2.26 billion in Opdivo sales in the first quarter of 2025.
With a strong cash position and some clinical milestones expected later this year, investor focus remains on IMCR stock.
IMCR’s Strong Rank & Rising Estimates
Immunocore has a Zacks Rank #1 (Strong Buy). In the past 30 days, estimates for IMCR’s 2025 loss per share have narrowed from $1.50 to 86 cents. During the same time, loss per share estimates for 2026 have narrowed from $1.68 to $1.34.
Immunocore Holdings PLC Sponsored ADR Price and Consensus
Immunocore Holdings PLC Sponsored ADR price-consensus-chart | Immunocore Holdings PLC Sponsored ADR Quote
Another Stock to Consider
Another drug/biotech stock to consider is CorMedix (CRMD - Free Report) , which currently carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, 2025 earnings estimates for CorMedix have improved from 72 cents per share to 93 cents per share. CRMD shares have surged 51.3% year to date.
CRMD’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 25.82%.